Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Transcription factor p65, encoded by the RELA gene, is a key subunit of the nuclear factor kappa B (NF-κB) transcription factor complex, most commonly functioning as a heterodimer with the p50 subunit. In resting cells, this complex is sequestered in an inactive state in the cytoplasm by inhibitory IκB proteins. Upon stimulation by pro-inflammatory cytokines, pathogens, or cellular stress, IκB is phosphorylated and degraded, allowing the p65-containing dimer to translocate into the nucleus, where it binds to specific DNA response elements to drive the transcription of genes involved in immune responses, inflammation, cell survival, and proliferation.
Dysregulation and constitutive activation of p65 are strongly implicated in the pathogenesis of chronic inflammatory diseases, autoimmune disorders, and various cancers, where it promotes tumor cell survival, metastasis, and resistance to therapy. Consequently, p65 is a highly sought-after therapeutic target. Pharmacological modulation of this pathway is achieved through diverse mechanisms, including direct inhibition of p65 nuclear translocation, blocking its DNA-binding activity, preventing upstream IκB degradation, or modulating post-translational modifications like phosphorylation and acetylation. However, because of its essential role in normal immunity and cell survival, systemic and broad inhibition of p65 poses significant safety challenges, including immunosuppression and potential hepatotoxicity.
Inhibition of nuclear translocation, inhibition of DNA binding, inhibition of IκB degradation, inhibition of p65 acetylation, and inhibition of transactivation
9 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Transcription factor p65 (RELA).